EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators

Joy Mouanes-Abelin iD, Christelle Pomares iD, José G Montoya iD, Morgane Pondrom, Lucille DE Maria iD, Andrea J Zimmer iD, Carlos A Gomez

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70263 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Joy Mouanes-Abelin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology, Hôpital de l'ARCHET, Nice, France. Hauptthemen laut MEDLINE: Toxoplasmosis, Immunocompromised Host, Immunologic Factors, Immunomodulating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toxoplasmosis has long been recognized as a serious complication in immunocompromised host, particularly those with advanced HIV/AIDS, hematopoietic stem‐cell transplantation (HSCT), solid‐organ transplant (SOT), and hematological malignancies. The rapid expansion of targeted immunomodulators, including chimeric antigen receptor T‐cell (CAR‐T) therapies, monoclonal antibodies, and small‐molecule inhibitors, is creating new at‐risk populations beyond traditional transplant settings. We present a 9‐year‐old boy with high‐risk B‐cell acute lymphoblastic leukemia (B‐ALL), who developed prolonged fever and macrophage activation syndrome (MAS). After an extensive unrevealing workup, disseminated acute toxoplasmosis was identified incidentally on bone marrow aspirate via morphologic identification of tachyzoites and confirmed by Toxoplasma gondii PCR. This case exemplifies the emerging threat of toxoplasmosis in non‐transplant immunomodulated hosts and supports three core mitigation strategies. First, baseline Toxoplasma IgG and IgM serology should be obtained in all patients initiating targeted immunotherapy, recognizing that B‐cell depletion or hypogammaglobulinemia may render IgG unreliable, and that IgM may be falsely negative, delayed, or persistently positive in immunocompromised individuals. Second, targeted PCR from clinically relevant compartments or metagenomic next‐generation sequencing when conventional diagnostics is unrevealing should be applied early. Third, prevention requires a bundled approach: baseline screening, patient education for seronegative individuals, and trimethoprim‐sulfamethoxazole prophylaxis with or without serial qPCR monitoring for seropositive patients. Toxoplasmosis is no longer a transplant‐exclusive concern. As targeted immunomodulators reshape practice across rheumatology, oncology, neurology, and autoimmune disease, infectious diseases specialists must lead efforts to raise cross‐specialty awareness, establish guidelines, and build registries to define the true burden of toxoplasmosis in these growing populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmosisImmunocompromised HostImmunologic FactorsImmunomodulating AgentsHumansMaleChildToxoplasmaMacrophage Activation SyndromeImmunoglobulin GImmunoglobulin MAntibodies, Protozoan

Stichwörter der Autor:innen

CAR T‐cell therapyPCRToxoplasma gondiibiologicsdisseminated toxoplasmosishematologic malignancymacrophage activation syndrometargeted immunotherapytoxoplasmosis

Substanzen

Immunoglobulin GImmunoglobulin MAntibodies, ProtozoanImmunologic FactorsImmunomodulating Agents

Autor:innen und Institutionen

  • Laboratory of Hematology, Hôpital de l'ARCHET, Nice, France.
  • Laboratoire De Parasitologie-Mycologie, Centre Hospitalier Universitaire De Nice, Inserm U 1065, Hôpital de l'ARCHET, Université De La Côte d'Azur, Nice, France.
  • Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Sutter Health, Palo Alto Medical Foundation, Palo Alto, California, USA.
  • Pediatric Onco-Hematology Department, Hôpital de l'ARCHET, Nice, France.
  • Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Joy Mouanes-Abelin, Christelle Pomares, José G Montoya, Lucille DE Maria, Andrea J Zimmer

Zitieren

APA

Mouanes-Abelin, J., Pomares, C., Montoya, J. G., Pondrom, M., Maria, L., Zimmer, A. J., & Gomez, C. A. (2026). Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators. Transplant Infectious Disease. https://doi.org/10.1111/tid.70263

Vancouver

Mouanes-Abelin J, Pomares C, Montoya JG, Pondrom M, Maria L, Zimmer AJ, et al. Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators. Transplant Infectious Disease. 2026. doi:10.1111/tid.70263

BibTeX
@article{MouanesAbelin2026,
  author = {Mouanes-Abelin, Joy and Pomares, Christelle and Montoya, José G and Pondrom, Morgane and Maria, Lucille DE and Zimmer, Andrea J and Gomez, Carlos A},
  title = {Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70263}
}
Kostenlos starten →